World leading industrial thread and textile crafts business Coats plc has launched a new range of anti-microbial sewing threads that inhibits the growth of microbes and bacteria around seams.
The treated sewing threads, which have anti-bacterial and anti-fungal properties, are a world first and will be marketed under the name ‘Coats Protect’. The innovative treatment was developed in Coats’ North American laboratories and delivers maximum protection from microbes when applied to Coats’ high quality thread products.
Coats has a long history of pioneering landmark innovation. Many of its product developments in threads, zips and color technology, as well as manufacturing processes, have become global industry standards.
Frazer Smith, Chief Commercial Officer, Coats plc, said: ‘A key element of our growth strategy is to continue developing innovative new products and services that meet our customers’ ever changing needs. We are excited about the launch of Coats Protect: another example of our strong research and development programme.’
The anti-microbial treatment creates a “zone of inhibition” that helps prevent the growth of odour and stain causing bacteria and pathogens around the seam. The treatment is available around the world for Coats’ thread and will provide peace of mind and enhanced product quality for our customers and consumers.
Anti-microbial thread can be used in a wide range of sewing applications and benefits include helping: keep products sterile; prevent product deterioration; fight mould and mildew and provide stain resistance. Many products, such as athletic footwear, hospital furnishings, operating theatre beds, muscle supports, hospital gowns, military tactical vests, helmets and outdoor goods need continued protection from fungi and odour causing bacteria, making them ideal applications for Coats Protect.
About Coats
With a rich heritage established in the 1750s, Coats is the world's leading industrial thread and textile crafts business, at home in more than 70 countries, employing 20,000 people across six continents. Revenues in 2011 were US$1.7bn.
